--> Karyopharm Therapeutics | Biotech

Karyopharm Therapeutics



About Us

Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.

Our company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with cancer and other serious diseases. Our novel approach to cancer treatment involves targeting the export of specific proteins in a cancer cell’s nucleus with SINE technology. Our primary focus is on developing novel drugs which we hope will help treat patients with certain blood cancers or solid tumor malignancies.

Rep/Contact Info

Brian Austad
Senior VP, Pharmaceutical Sciences
Robin Balin
Ran Frenkel
EVP, Chief Development Officer
Anat Haas Mizrahi
General Manager, Karyopharm Israel
Ian Karp
Senior VP, Investor and Public Relations
Michael G. Kauffman
Founder, CEO
Yosef Landesman
Senior VP, Research & Translational Medicine
Tanya Lewis
EVP, Chief Regulatory and Quality Officer
Mike Mano
Senior VP, General Counsel
Michael Mason
Chief Financial Officer
Ronit Milstein
Vice President, Operations
Stephen Mitchener
Chief Business Officer
Perry Monaco
Senior VP, Sales
Steven Rotman
Chief People and Corporate Engagement Officer
Pierre S. Sayad
VP, Global Medical and Scientific Affairs
Sharon Shacham
Founder, President, Chief Scientific Officer
Jatin Shah
EVP, Chief Medical Officer